977 related articles for article (PubMed ID: 17299012)
1. Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus.
Maclayton DO; Hall RG
Ann Pharmacother; 2007 Feb; 41(2):235-44. PubMed ID: 17299012
[TBL] [Abstract][Full Text] [Related]
2. Pharmacotherapy for methicillin-resistant Staphylococcus aureus nosocomial pneumonia.
Segarra-Newnham M; Church TJ
Ann Pharmacother; 2012 Dec; 46(12):1678-87. PubMed ID: 23232021
[TBL] [Abstract][Full Text] [Related]
3. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid.
Stein GE; Wells EM
Curr Med Res Opin; 2010 Mar; 26(3):571-88. PubMed ID: 20055750
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial treatment of nosocomial meticillin-resistant Staphylococcus aureus (MRSA) pneumonia: current and future options.
Welte T; Pletz MW
Int J Antimicrob Agents; 2010 Nov; 36(5):391-400. PubMed ID: 20724119
[TBL] [Abstract][Full Text] [Related]
5. Antibiotic therapy of methicillin-resistant Staphylococcus aureus in critical care.
Tverdek FP; Crank CW; Segreti J
Crit Care Clin; 2008 Apr; 24(2):249-60, vii-viii. PubMed ID: 18361944
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
Estes L; Orenstem R
Clin Ther; 2007 Apr; 29(4):759-60; author reply 760-1. PubMed ID: 17617300
[No Abstract] [Full Text] [Related]
7. Vancomycin versus linezolid in the treatment of methicillin-resistant Staphylococcus aureus nosocomial pneumonia: implications of the ZEPHyR trial.
Alaniz C; Pogue JM
Ann Pharmacother; 2012 Oct; 46(10):1432-5. PubMed ID: 22947593
[TBL] [Abstract][Full Text] [Related]
8. Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.
Micek ST
Clin Infect Dis; 2007 Sep; 45 Suppl 3():S184-90. PubMed ID: 17712745
[TBL] [Abstract][Full Text] [Related]
9. A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus.
Scheinfeld N
J Drugs Dermatol; 2007 Jan; 6(1):97-103. PubMed ID: 17373167
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
Estes L; Orenstein R
Clin Ther; 2007 Feb; 29(2):381-3; author reply 383-4. PubMed ID: 17472831
[No Abstract] [Full Text] [Related]
11. Impact of weight on treatment efficacy and safety in complicated skin and skin structure infections and nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
Puzniak LA; Morrow LE; Huang DB; Barreto JN
Clin Ther; 2013 Oct; 35(10):1557-70. PubMed ID: 24011955
[TBL] [Abstract][Full Text] [Related]
12. Treatment options for nosocomial pneumonia due to MRSA.
Niederman MS
J Infect; 2009 Sep; 59 Suppl 1():S25-31. PubMed ID: 19766886
[TBL] [Abstract][Full Text] [Related]
13. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia.
Wunderink RG; Rello J; Cammarata SK; Croos-Dabrera RV; Kollef MH
Chest; 2003 Nov; 124(5):1789-97. PubMed ID: 14605050
[TBL] [Abstract][Full Text] [Related]
14. European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid.
Chastre J; Blasi F; Masterton RG; Rello J; Torres A; Welte T
Clin Microbiol Infect; 2014 Apr; 20 Suppl 4():19-36. PubMed ID: 24580739
[TBL] [Abstract][Full Text] [Related]
15. A holistic approach to MRSA eradication in critically ill patients with MRSA pneumonia.
Wenisch C; Laferl H; Szell M; Smolle KH; Grisold A; Bertha G; Krause R
Infection; 2006 Jun; 34(3):148-54. PubMed ID: 16804658
[TBL] [Abstract][Full Text] [Related]
16. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
McKinnon PS; Sorensen SV; Liu LZ; Itani KM
Ann Pharmacother; 2006 Jun; 40(6):1017-23. PubMed ID: 16720705
[TBL] [Abstract][Full Text] [Related]
17. Treatment of infections caused by resistant Staphylococcus aureus.
Anstead GM; Quinones-Nazario G; Lewis JS
Methods Mol Biol; 2007; 391():227-58. PubMed ID: 18025681
[TBL] [Abstract][Full Text] [Related]
18. The ZEPHyR study: a randomized comparison of linezolid and vancomycin for MRSA pneumonia.
Chavanet P
Med Mal Infect; 2013 Dec; 43(11-12):451-5. PubMed ID: 24238896
[TBL] [Abstract][Full Text] [Related]
19. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study.
Wunderink RG; Niederman MS; Kollef MH; Shorr AF; Kunkel MJ; Baruch A; McGee WT; Reisman A; Chastre J
Clin Infect Dis; 2012 Mar; 54(5):621-9. PubMed ID: 22247123
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study.
Florescu I; Beuran M; Dimov R; Razbadauskas A; Bochan M; Fichev G; Dukart G; Babinchak T; Cooper CA; Ellis-Grosse EJ; Dartois N; Gandjini H;
J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i17-28. PubMed ID: 18684703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
